The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer

Ashwaq Al Olayan; Hamad Al Hussaini; Abdul Rahman Jazieh

doi:10.1016/j.jiph.2012.09.004

The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer

J Infect Public Health. 2012 Dec:5 Suppl 1:S50-60. doi: 10.1016/j.jiph.2012.09.004. Epub 2012 Nov 6.

Authors

Ashwaq Al Olayan¹, Hamad Al Hussaini, Abdul Rahman Jazieh

Affiliation

¹ Division of Adult Medical Oncology, Department of Oncology, King Abdulaziz Medical City for National Guard - King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. alolayanas@ngha.med.sa

PMID: 23244189
DOI: 10.1016/j.jiph.2012.09.004

Abstract

Targeting epidermal growth factor receptor (EGFR) is an important treatment option for non-small cell lung cancer (NSCLC). These targeted therapies have been studied extensively in NSCLC in first line and subsequent lines, including maintenance in empiric fashion or in patients with tumors harboring the EGFR mutations. In this manuscript, we will review in details the evolutions of these targeted therapy in the management of NSCLC.

Publication types

Review

MeSH terms

Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / pharmacology
Carcinoma, Non-Small-Cell Lung / drug therapy*
ErbB Receptors / antagonists & inhibitors*
Humans
Lung Neoplasms / drug therapy*

Substances

Antineoplastic Agents
ErbB Receptors